Phibro Animal Health (NASDAQ:PAHC) Downgraded to “Buy” Rating by StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

Several other analysts have also recently weighed in on the stock. Morgan Stanley raised their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Barclays raised their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Trading Down 6.7 %

NASDAQ PAHC opened at $20.05 on Friday. The firm has a 50 day simple moving average of $22.75 and a 200-day simple moving average of $21.10. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. Phibro Animal Health has a one year low of $10.03 and a one year high of $25.98. The firm has a market cap of $812.09 million, a price-to-earnings ratio of 46.63, a PEG ratio of 0.58 and a beta of 0.53.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sofinnova Investments Inc. purchased a new position in Phibro Animal Health in the 2nd quarter valued at $3,975,000. Geode Capital Management LLC boosted its position in shares of Phibro Animal Health by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after purchasing an additional 27,201 shares in the last quarter. Barclays PLC boosted its position in shares of Phibro Animal Health by 25.7% during the 3rd quarter. Barclays PLC now owns 143,337 shares of the company’s stock worth $3,228,000 after purchasing an additional 29,271 shares in the last quarter. Algert Global LLC boosted its position in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after purchasing an additional 59,850 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Phibro Animal Health by 3.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock worth $548,000 after purchasing an additional 729 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.